VolitionRx Limited (VNRX) Q3 2024 Earnings Call Transcript Summary
VolitionRx Limited (VNRX) Q3 2024 Earnings Call Transcript Summary
Operating expenses dropped by 28% compared to the same quarter of the previous year, contributing to a decrease in cash used in operations by 36% year-over-year.The following is a summary of the VolitionRx Limited (VNRX) Q3 2024 Earnings Call Transcript:
以下是volitionrx有限公司（VNRX）2024年第三季度業績會會議記錄的摘要：
Financial Performance:
財務表現：
VolitionRx reported significant growth, with a third-quarter revenue of $475,000, marking a 307% increase compared to the same quarter the previous year.
Year-to-date revenues have doubled to approximately $1 million, representing a 96% growth over the previous period.
Operating expenses dropped by 28% compared to the same quarter of the previous year, contributing to a decrease in cash used in operations by 36% year-over-year.
The company also secured commitments for $2.2 million in non-dilutive funding from the Walloon Region in Belgium.
volitionrx報告了顯著增長，第三季度營業收入爲475,000美元，與上年同期相比增長了307%。
截至目前的營業收入已達約100萬，較前一時期增長了96%。
營業費用較上年同期下降了28%，使得年度運營現金使用下降了36%。
公司還獲得了來自比利時瓦隆地域板塊的220萬非稀釋性資金的承諾。
Business Progress:
業務進展：
VolitionRx sold over 110,000 Nu.Q Vet cancer tests in the first three quarters, significantly up from 58,000 in the entire previous year.
The company has expanded Nu.Q Vet tests availability to 17 countries.
Significant advancements in human and veterinary clinical studies, particularly in lung cancer and sepsis, with major studies set to conclude in Q4 2025.
Ongoing negotiations for commercial licensing agreements that could potentially position the company's platform in national lung cancer screening programs across multiple regions.
volitionrx在前三個季度銷售了超過110,000個Nu.Q Vet癌症檢測，比去年全年58,000個有了顯著增加。
公司已將Nu.Q獸醫測試的可用性擴展到17個國家。
在盈健醫療和獸醫臨床研究方面，特別是在肺癌和膿毒症方面，取得了顯著進展，主要研究預計將在2025年第四季度完成。
正在進行商業許可協議的談判，這可能將公司的平台定位於多個地域板塊的國家肺癌篩查項目中。
Opportunities:
機會：
Strong growth trajectories in Nu.Q Vet tests alongside penetration into new international markets present significant revenue opportunities.
Upcoming negotiations and potential deals in licensing across the human health sector, particularly in oncology and sepsis, indicating prospects for significant monetization of the company's IPs.
The involvement in national screening programs could potentially elevate the company's profile and open up further markets.
Nu.Q獸醫測試的強勁增長軌跡以及進入新的國際市場的滲透，爲營業收入提供了重大機會。
即將進行的談判和在盈健醫療板塊，特別是在腫瘤學和膿毒症方面的潛在許可交易，顯示出公司知識產權的重大貨幣化前景。
參與國家篩查項目可能會提升公司的知名度，並打開更多市場。
Risks:
風險：
Dependence on the successful expansion and acceptance of Nu.Q Vet and human diagnostic tests in new markets.
The company's financial future highly contingent on securing lucrative licensing deals and partnerships in the diagnostic and biotechnical space.
依賴於Nu.Q Vet和人類診斷測試在新市場成功擴展和被接受。
公司的財務未來高度依賴於在診斷和生物技術領域獲得豐厚的許可交易和合作夥伴關係。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
